Choindroitinase ABC I-mediated enhancement of oncolytic virus spread and anti tumor efficacy: A Mathematical model

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Kim, Yangjin ^a,c   Lee, Hyun Geun ^b   Dmitrieva, Nina ^a   Kim, Junseok ^b   Kaur, Balveen ^a   Friedman, Avner ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Korea University   (South Korea)

^c Konkuk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; CHOINDROITINASE ABC I; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; CHONDROITIN ABC LYASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL KILLING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRATUMORAL DRUG ADMINISTRATION; MATHEMATICAL MODEL; METASTASIS; MULTIPLE CANCER; ONCOLYTIC VIROTHERAPY; PREDICTION; PRIMARY TUMOR; TUMOR MICROENVIRONMENT; TUMOR VOLUME; BACTERIUM; BIOLOGICAL MODEL; BRAIN; BRAIN NEOPLASMS; ENZYMOLOGY; GLIOMA; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE;

BACTERIA; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHONDROITIN ABC LYASE; GLIOMA; HUMANS; MODELS, BIOLOGICAL; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 84904567760     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102499     Document Type: Article

References (101)

1. Kim Y, Roh S, Lawler S, Friedman A (2011) miR451 and AMPK/MARK mutual antagonism in glioma cells migration and proliferation. PLoS One 6: e28293.
2. Jacobs V, Valdes P, Hickey W, Leo JD (2011) Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model. ASN NEURO 3: e00063.
3. Barcellos-Hoff M, Newcomb E, Zagzag D, Narayana A (2009) Therapeutic targets in malignant glioblastoma microenvironment. Semin Radiat Oncol 19: 163-70.
4. Msaouel P, Dispenzieri A, Galanis E (2009) Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther 11: 43-53.
5. Kaur B, Cripe T, Chiocca E (2009) Buy one get one free: armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther 9: 341-355.
6. Kuriyama N, Kuriyama H, Julin C, Lamborn K, Israel M (2000) Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Hum Gene Ther 11: 2219-2230.
7. Kim J, Lee Y, Kim H, Huang J, Yoon A, et al. (2006) Relaxin expression from tumor targeting adenoviruses and its intra tumoral spread, apoptosis induction, and efficacy. Gene Ther 98: 1482-1493. (Pubitemid 44605593)
8. Haseley A, Alvarez-Breckenridge C, Chaudhury AR, Kaur B (2009) Advances in oncolytic virus therapy for glioma. Recent patents on CNS drug discovery 4: 1.
9. Hong C, Fellows W, Niranian A, Alber S, Watkins S, et al. (2010) Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic hsv vector infection. Gene Ther 17: 1200-1205.
10. Choi I, Lee Y, Yoo J, Yoon A, Kim H, et al. (2010) Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene therapy 17: 190-201.
11. Dmitrieva N, Yu L, Viapiano M, Cripe T, Chiocca E, et al. (2011) Choindroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Clin Cancer Res 17: 1362-72.
12. Haseley A, Boone S, Wojton J, Yu L, Yoo JY, et al. (2012) Extracellular matrix protein ccn1 limits oncolytic efficacy in glioma. Cancer research 72: 1353-1362.
13. Viapiano M, Matthews R (2006) From barriers to bridges: chondroitin sulfate proteoglycans in neuropathology. Trends Mol Med 12: 488-496. (Pubitemid 44441998)
14. Dwyer CA, Matthews RT (2011) The neural extracellular matrix, cell adhesion molecules and proteolysis in glioma invasion and tumorigenicity. In: Garam M, editor, Molecular Targets of CNS Tumors, InTech. pp. 239-264.
15. Wang C, Tong X, Yang F (2014) Bioengineered 3D brain tumor model to elucidate the effects of matrix stiffness on glioblastoma cell behavior using PEG-based hydrogels. Molecular pharmaceutics.
16. Ananthanarayanan B, Kim Y, Kumar S (2011) Elucidating the mechanobiology of malignant brain tumors using a brain matrix-mimetic hyaluronic acid hydrogel platform. Biomaterials 32: 7913-7923.
17. Delpech B, Maingonnat C, Girard N, Chauzy C, Olivier A, et al. (1993) Hyaluronan and hyaluronectin in the extracellular matrix of human brain tumour stroma. European Journal of Cancer 29: 1012-1017. (Pubitemid 23126704)
18. Patan S (2004) Vasculogenesis and angiogenesis. In: Kirsch M, Black PM, editors, Angiognesis in Brain Tumors, Kluwer Academic Publishers. pp. 3-32.
19. Klekner A (2013) Brain tumor invasion and angiogenesis. In: Lichtor T, editor, Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications, InTech. pp. 3-36.
20. Zimmermann D, Dours-Zimmermann M (2008) Extracellular matrix of the central nervous system: from neglect to challenge. Histochem Cell Biol 130: 635-53.
21. Ramanujan S, Pluen A, McKee T, Brown E, Boucher Y, et al. (2002) Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. Biophys J 83: 1650-60. (Pubitemid 34977735)
22. Moon L, Asher R, Fawcett J (2003) Limited growth of severed cns axons after treatment of adult rat brain with hyaluronidase. J Neurosci Res 71: 23-37. (Pubitemid 36008399)
23. Netti P, Berk D, Swartz M, Grodzinsky A, Jain R (2000) Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 60: 2497-2503. (Pubitemid 30262444)
24. Eikenes L, Bruland O, Brekken C, Cde LD (2004) Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res 64: 4768-73. (Pubitemid 38930817)
25. Guedan S, Rojas J, Gros A, Mercade E, Cascallo M, et al. (2010) Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 18: 1275-1283.
26. Wang Y, Luo W, Reiser G (2008) Trypsin and trypsin-like proteases in the brain: proteolysis and cellular functions. Cell Mol Life Sci 65: 237-252. (Pubitemid 351161480)
27. Daginakatte G, Gutmann D (2007) Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet 16: 1098-1112. (Pubitemid 47062730)
28. Lin R, Kwok J, Crespo D, Fawcett J (2008) Chondroitinase abc has a long-lasting effect on chondroitin sulphate glycosaminoglycan content in the injured rat brain. J Neurochem 104: 400-408. (Pubitemid 350293887)
29. Viapiano M, Lawler S (2009) Glioma Invasion: Mechanisims and Therapeutic Challenges. Humana Press.
30. Arslan F, Bosserhoff A, Nickl-Jockschat T, Doerfelt A, Bogdahn U, et al. (2007) The role of versican isoforms v0/v1 in glioma migration mediated by transforming growth factor-beta2. Br J Cancer 96: 1560-8. (Pubitemid 46762960)
31. Viapiano M, Hockfield S, Matthews R (2008) Behab/brevican requires adamts-mediated proteolytic cleavage to promote glioma invasion. J Neurooncol 88: 261-272.
32. Grumet M, Friedlander D, Sakurai T (1996) Functions of brain chondroitin sulfate proteoglycans during developments: interactions with adhesion molecules. Perspect Dev Neurobiol 3: 319-330. (Pubitemid 126839139)
33. Mok W, Boucher Y, Jain R (2007) Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res 67: 10664-10668. (Pubitemid 350145891)
34. Bruckner G, Bringmann A, Hartig W, Koppe G, Delpech B, et al. (1998) Acute and long-lasting changes in extracellular-matrix chondroitin-sulphate proteoglycans induced by injection of chondroitinase abc in the adult rat brain. Exp Brain Res 121: 300-310. (Pubitemid 28371962)
35. Thuret S, Moon L, Gage F (2006) Therapeutic interventions after spinal cord injury. Nat Rev Neurosci 7: 628-643. (Pubitemid 44106745)
36. Kim Y, Lawler S, Nowicki M, Chiocca E, Friedman A (2009) A mathematical model of brain tumor: pattern formation of glioma cells outside the tumor spheroid core. J Theo Biol 260: 359-371.
37. Swanson K, Alvord E, Murray J (2003) Virtual resection of gliomas: Effect of extent of resection on recurrence. Math Comp Modelling 37: 1177-1190. (Pubitemid 36761624)
38. Harpold H, Alvord EC Jr, Swanson K (2007) The evolution of mathematical modeling of glioma proliferation and invasion. J Neuropathol Exp Neurol 66: 1-9. (Pubitemid 46066783)
39. Corwin D, Holdsworth C, Rockne R, Trister A, Mrugala M, et al. (2013) Toward patient-specific, biologically optimized radiation therapy plans for the treatment of glioblastoma. PLoS One 8.
40. Badoual M, Deroulers C, Aubert M, Grammaticos B (2010) Modelling intercellular communication and its effects on tumour invasion. Phys Biol 7: 046013.
41. Gerin C, Pallud J, Grammaticos B, Mandonnet E, Deroulers C, et al. (2012) Improving the time-machine: estimating date of birth of grade ii gliomas. Cell proliferation 45: 76-90.
42. Aubert M, Badoual M, Freol S, Christov C, Grammaticos B (2006) A cellular automaton model for the migration of glioma cells. Phys Biol 3: 93-100. (Pubitemid 44043089)
43. Hatzikirou H, Basanta D, Simon M, Schaller K, Deutsch A (2010) 'go or grow': the key to the emergence of invasion in tumour progression? Math Med Biol 27: 255-281.
44. Chauviere A, Preziosi L, Byrne H (2010) A model of cell migration within the extracellular matrix based on a phenotypic switching mechanism. Math Med Biol 27: 255-281.
45. Pham K, Chauviere A, Hatzikirou H, Li X, Byrne H, et al. (2011) Density-dependent quiescence in glioma invasion: instability in a simple reaction-diffusion model for the migration/proliferation dichotomy. Journal of Biological dynamics: doi: 10.1080/17513758.2011.590610.
46. Kim Y (2013) Regulation of cell proliferation and migration in glioblastoma: New therapeutic approach. Frontiers in Molecular and Cellular Oncology 3: 53.
47. Kim Y, Roh S (2013) A hybrid model for cell proliferation and migration in glioblastoma. Discrete and Continuous Dynamical Systems-B 18: 969-1015.
48. Lowengrub J, Frieboes H, Jin F, Chuang Y, Li X, et al. (2010) Nonlinear modelling of cancer: bridging the gap between cells and tumours. Nonlinearity 23: R1.
49. Rejniak K, Anderson A (2011) Hybrid models of tumor growth. WIRES Syst Biol Med 3: 115-125.
50. Friedman A, Tian J, Fulci G, Chiocca E, Wang J (2006) Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res 66: 2314-9.
51. Muir E, Fyfe I, Gardiner S, Li L, Warren P, et al. (2010) Modification of N-glycosylation sites allows secretion of bacterial chondroitinase ABC from mammalian cells. J Biotechnol 145: 103-10.
52. Gladson C (1999) The extracellular matrix of gliomas: modulation of cell function. J Neuropathol Exp Neurol 58: 1029-1040.
53. Bellail A, Hunter S, Brat D, Tan C, Meir EV (2004) Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol 36: 1046-1069. (Pubitemid 38501557)
54. Kim Y, Friedman A (2010) Interaction of tumor with its microenvironment: A mathematical model. Bull Math Biol 72: 1029-1068.
55. Kim Y, Stolarska M, Othmer H (2011) The role of the microenvironment in tumor growth and invasion. Prog Biophys Mol Biol 106: 353-379.
56. Markert J, Liechty P, Wang W, Gaston S, Braz E, et al. (2009) Phase ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 17: 199-207.
57. Davis F, McCarthy B (2001) Current epidemiological trends and surveillance issues in brain tumors. Expert Rev Anticancer Ther 1: 395-401. (Pubitemid 34679431)
58. Ozduman K, Wollmann G, Piepmeier J, van den Pol A (2008) Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J Neurosci 28: 1882-93. (Pubitemid 351302677)
59. Pardridge W (2002) Drug and gene delivery to the brain: the vascular route. Neuron 36: 555-8.
60. Pardridge W (2007) Blood-brain barrier delivery. Drug Discov Today 12: 54-61.
61. Pope W, Sayre J, Perlina A, Villablanca J, Mischel P, et al. (2005) Mr imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 26: 2466-74.
62. Parker J, Bauer D, Cody J, Markert J (2009) Oncolytic viral therapy of malignant glioma. Neurotherapeutics 6: 558-569.
63. Choucair A, Levin V, Gutin P, Davis R, Silver P, et al. (1986) Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 65: 654-8. (Pubitemid 17177515)
64. Pasquier B, Pasquier D, N'Golet A, Panh M, Couderc P (1980) Extraneural metastases of astrocytomas and glioblastomas: clinicopathological study of two cases and review of literature. Cancer 45: 112-25. (Pubitemid 10214965)
65. Ronnov-Jessen L, Petersen O, Bissell M (1996) Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 76: 69-125. (Pubitemid 26048279)
66. Cheema T, Wakimoto H, Fecci P, Ning J, Kuroda T, et al. (2013) Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Nat Acad Sci USA ahead of print: doi:10.1073/pnas.1307935110
67. Whitley R, Markert J (2013) Viral therapy of glioblastoma multiforme. Proc Natl Acad Sci USA 110: 11672-11673.
68. Giese A, Bjerkvig R, Berens M, Westphal M (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21: 1624-36. (Pubitemid 46594118)
69. Beadle C, Assanah M, Monzo P, Vallee R, Rosenfield S, et al. (2008) The role of myosin II in glioma invasion of the brain. Mol Biol Cell 19: 3357-3368.
70. Lun X, Senger D, Alain T, Oprea A, Parato K, et al. (2006) Effects of intravenously administered recombinant vesicular stomatitis virus (vsv(deltam51)) on multifocal and invasive gliomas. J Natl Cancer Inst 98: 1546-1557. (Pubitemid 44680906)
71. Pardridge W (2006) Molecular trojan horses for blood?brain barrier drug delivery. Current Opinion in Pharmacology 6: 494-500.
72. Khuri F, Nemunaitis J, Ganly I, Arseneau J, Tannock I, et al. (2000) A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6: 879-85. (Pubitemid 30644745)
73. Pulkkanen K, Yla-Herttuala S (2005) Gene therapy for malignant glioma: current clinical status. Mol Ther 12: 585-98. (Pubitemid 41350140)
74. Puumalainen A, Vapalahti M, Agrawal R, Kossila M, Laukkanen J, et al. (1998) Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther 9: 1769-1774. (Pubitemid 28418747)
75. Harsh G, Deisboeck T, Louis D, Hilton J, Colvin MM, et al. (2000) Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J Neurosurg 92: 804-11. (Pubitemid 30243929)
76. Ram Z, Culver K, Oshiro E, Viola J, DeVroom H, et al. (1997) Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3.
77. Balachandran S, Porosnicu M, Barber G (2001) Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or Myc function and involves the induction of apoptosis. J Virol 75: 3474-9. (Pubitemid 32225911)
78. Connor J, Naczki C, Koumenis C, Lyles D (2004) Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo. J Virol 78: 8960-70. (Pubitemid 39096508)
79. Wollmann G, Tattersall P, van den Pol A (2005) Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J Virol 79: 6005-22. (Pubitemid 40617207)
80. Kaur B, Chiocca E, Cripe T (2012) Oncolytic hsv-1 virotherapy: clinical experience and opportunities for progress. Curr Pharm Biotechnol 13: 1842-1851.
81. Gotoh N (2008) Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. Cancer Sci 99: 1319-25.
82. Black P, Agarwal P, Dinney C (2007) Targeted therapies in bladder cancer-an update. Urol Oncol 25: 433-8. (Pubitemid 47362765)
83. Green N, Morrison J, Hale S, Briggs S, Stevenson M, et al. (2008) Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. J Gene Med 10: 280-9. (Pubitemid 351359640)
84. Kim J, Kim P, Kim S, Yun C (2012) Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials. Biomaterials 33: 1838-50.
85. Verheije M, Lamfers M, Wurdinger T, Grinwis G, Gerritsen W, et al. (2009) Coronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastoma. J Virol 83: 7507-16.
86. Morrison J, Briggs S, Green N, Fisher K, Subr V, et al. (2008) Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. Mol Ther 16: 244-51. (Pubitemid 351168032)
87. Glasgow J, Everts M, Curiel D (2006) Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther 13: 830-44.
88. Nicklin S, Wu E, Nemerow G, Baker A (2005) The influence of adenovirus fiber structure and function on vector development for gene therapy. Mol Ther 12: 384-93. (Pubitemid 41150124)
89. MokW, Stylianopoulos T, Boucher Y, Jain R (2009) Mathematical modeling of herpes simplex virus distribution in solid tumors: implications for cancer gene therapy. Clin Cancer Res 15: 2352-60.
90. Kim Y, Stolarska M, Othmer H (2007) A hybrid model for tumor spheroid growth in vitro I: Theoretical development and early results. Math Models Methods in Appl Scis 17: 1773-1798.
91. Stolarska M, Kim Y, Othmer H (2009) Multiscale models of cell and tissue dynamics. Phil Trans Roy Soc A 367: 3525-3553.
92. ODonoghue J, Bardies M, Wheldon T (1995) Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36: 1902-9.
93. Gu W, Fu S, Wang Y, Li Y, Lu H, et al. (2009) Chondroitin sulfate proteoglycans regulate the growth, differentiation and migration of multipotent neural precursor cells through the integrin signaling pathway. BMC Neurosci 10: 1-15.
94. Silver DJ, Siebzehnrubl FA, Schildts MJ, Yachnis AT, Smith GM, et al. (2013) Chondroitin sulfate proteoglycans potently inhibit invasion and serve as a central organizer of the brain tumor microenvironment. The Journal of Neuroscience 33: 15603-15617.
95. Fryer H, Kelly G, Molinaro L, Hockfield S (1992) The high molecular weight cat-301 chondroitin sulfate proteoglycan from brain is related to the large aggregating proteoglycan from cartilage, aggrecan. Journal of Biological Chemistry 267: 9874-9883.
96. Heinegard D, Paulsson M, Inerot S, Carlstrom C (1981) A novel low-molecular weight chondroitin sulphate proteoglycan isolated from cartilage. Biochem J 197: 355-366. (Pubitemid 11013971)
97. Dutt S, Kléber M, Matasci M, Sommer L, Zimmermann DR (2006) Versican v0 and v1 guide migratory neural crest cells. Journal of biological chemistry 281: 12123-12131. (Pubitemid 43855476)
98. Dutt S, Matasci M, Sommer L, Zimmermann DR (2006) Guidance of neural crest cell migration: the inhibitory function of the chondroitin sulfate proteoglycan, versican. Scientific World Journal 6: 1114-7. (Pubitemid 44440813)
99. Viapiano MS, Bi WL, Piepmeier J, Hockfield S, Matthews RT (2005) Novel tumor-specific isoforms of behab/brevican identified in human malignant gliomas. Cancer research 65: 6726-6733. (Pubitemid 41060710)
100. Bignami A, Hosley M, Dahl D (1993) Hyaluronic acid and hyaluronic acid-binding proteins in brain extracellular matrix. Anat Embryol 188: 419-33. (Pubitemid 24000108)
101. Dahl D, Chi N, Miles L, Nguyen B, Bignami A (1982) Glial fibrillary acidic (GFA) protein in schwann cells: fact or artefact? J Histochem Cytochem 30: 912-918. (Pubitemid 13223542)